<DOC>
	<DOC>NCT01051414</DOC>
	<brief_summary>To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.</brief_summary>
	<brief_title>An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of â‰¥ 10*5* IU/mL (100,000 IU/mL) at screening Subjects with evidence of liver cirrhosis Evidence of HCC Coinfection with hepatitis B virus, HIV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>